Patents Examined by Jed A Kucharczk
-
Patent number: 12029739Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.Type: GrantFiled: January 8, 2024Date of Patent: July 9, 2024Assignee: KANAPH THERAPEUTICS INC.Inventors: Miyeon Kim, Dohyun Park, Dongsu Kim, Kyeongjin Yoon, Sungpil Choi, Sang Kyun Lim, Eu Ddeum Chung, Mijung Lee, Dahye Jeon, Soyeon Jang, Kyungik Lee, Jinhwan Kim, Eunji Kim, Jieun Min, Kangwoo Lee, Jakyung Yoo
-
Patent number: 12016933Abstract: A method of promoting axonal regeneration can include directing neuronal lipid synthesis away from triglyceride synthesis and toward phospholipid synthesis. The method can include administering to the patient a therapeutically effective amount of an inhibitor compound selected from the group consisting of a Lipin-1 inhibitor, a diglyceride acyltransferase inhibitor, and combinations thereof or administering a gene editing therapy to the patient that reduces expression of LIPIN1 or a diglyceride acyltransferase gene.Type: GrantFiled: November 25, 2020Date of Patent: June 25, 2024Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Chao Yang, Xu Wang, Kai Liu
-
Patent number: 12012396Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.Type: GrantFiled: August 2, 2023Date of Patent: June 18, 2024Assignee: Viracta Subsidiary, Inc.Inventors: Xiaohu Deng, Wanping Mai, Robert C. McRae, Biljana Nadjsombati
-
Patent number: 11986476Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones and their use as anti-tubercular agents are provided.Type: GrantFiled: September 13, 2023Date of Patent: May 21, 2024Assignee: KING FAISAL UNIVERSITYInventors: Katharigatta N. Venugopala, Keshab M. Bairagi, Pran Kishore Deb, Melendran Pillay, Mohamed A. Morsy, Susanta K. Nayak, Sandeep Chandrashekharappa, Osama I. Alwassil
-
Patent number: 11981694Abstract: Disclosed herein are acyclic thiol prodrugs, and pharmaceutical compositions thereof. The prodrugs and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example cystinosis, cystinuria, cancer neurodegenerative disease, Parkinson's disease, Huntington's disease, malaria, nonalcoholic fatty liver disease, radiation poisoning, arsenic poisoning, radioprotection, Wilson's disease or rheumatoid arthritis.Type: GrantFiled: December 28, 2022Date of Patent: May 14, 2024Assignee: Lilac Therapeutics, Inc.Inventors: Manoj Chandrasinhji Desai, Siva R. Kamma
-
Patent number: 11976065Abstract: The invention relates to novel crystalline forms of imiquimod formed with ferulic acid, acetic acid, coumaric acid, citric acid, or tartaric acid, to methods of making these cocrystals, and to compositions containing the cocrystals.Type: GrantFiled: June 23, 2021Date of Patent: May 7, 2024Assignee: CELISTA PHARM ACEUTICALS LLCInventor: Yogesh Dandiker
-
Patent number: 11964938Abstract: A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes.Type: GrantFiled: January 7, 2019Date of Patent: April 23, 2024Assignee: CELON PHARMA S.A.Inventors: Mateusz Mach, Radoslaw Dzida, Damian Smuga, Filip Stelmach, Mikolaj Matloka, Katarzyna Bazydlo, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
-
Patent number: 11958806Abstract: An object is to provide a method for easily producing maleimide (MI) in which trace amounts of residual acid components as impurities in a crude MI are efficiently reduced, that is, the acid value is sufficiently reduced. <1> A method for producing purified MI, comprising reducing an acid value of crude MI by 50% or more, by adding carbodiimide (CDI) to a solution comprising the crude MI to react an acid component in the crude MI with the CDI. <2> The method for producing purified MI, comprising adding 0.5% by mass or more and 8% by mass or less of the CDI with respect to a mass of the crude MI for reaction. <3> The method for producing purified MI, wherein the CDI is N,N?-diisopropyl carbodiimide (DIC). <4> The method for producing purified MI, comprising removing a urea derivative of the CDI (CDI-U) by-produced when reacting the acid component in the crude MI with the CDI.Type: GrantFiled: September 29, 2020Date of Patent: April 16, 2024Assignee: UNITIKA LTD.Inventors: Yuki Yamada, Tatsuya Morikita, Yosuke Sugimoto, Takeshi Yoshida, Akira Shigeta, Yoshiaki Echigo
-
Patent number: 11951100Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as macular degeneration and the like.Type: GrantFiled: September 1, 2023Date of Patent: April 9, 2024Assignee: Belite Bio, LLCInventors: Yu-Hsin Tom Lin, Cheng-Chi Irene Wang
-
Patent number: 11939330Abstract: Novel pyrido[3,4-b]indole-6-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3,4-b]indole-6-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: August 25, 2023Date of Patent: March 26, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11932616Abstract: The invention is directed to a process for the ring-opening of a cycloadduct obtainable from a reaction of a furanic compound and a diene, said process comprising contacting the cycloadduct with an acidic mixture comprising sulfuric acid and an activating agent to obtain a ring-opened product. The present invention is particularly directed a continuous process.Type: GrantFiled: April 30, 2019Date of Patent: March 19, 2024Assignee: Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNOInventors: Marc Crockatt, Johan Urbanus
-
Patent number: 11912706Abstract: The present invention relates to novel solid crystalline form of N-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzo [4,5]imidazo[1,2-a][1,8]naphthyridine-6-carbaxomide, processes for the preparation thereof, compositions thereof and method of use thereof.Type: GrantFiled: March 28, 2018Date of Patent: February 27, 2024Assignee: PIMERA, INC.Inventor: Mustapha Haddach
-
Patent number: 11912701Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein Rx, Ry, Rz and Rzz are selected from: a) Rx and Ry are F and Rz and Rzz are H; b) Rx, Ry and Rzz are independently halogen and Rz is H; c) Rx Rz and Rzz are independently halogen and Ry is H; and d) Rx Ry and Rz are independently halogen and Rzz is H.Type: GrantFiled: July 16, 2019Date of Patent: February 27, 2024Assignee: HepaRegeniX GmbHInventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
-
Patent number: 11905231Abstract: The present disclosure relates to solid forms and salts, crystalline and otherwise, of (E)-2-[[3-(3-methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid and pharmaceutical compositions comprising same. The use of such solid forms, salts, and pharmaceutical compositions, for treating, preventing, or ameliorating diseases or conditions associated with fibrosis, inflammation and/or proliferation are disclosed.Type: GrantFiled: July 18, 2023Date of Patent: February 20, 2024Assignee: Certa Therapeutics Pty LtdInventors: Darren James Kelly, Gareth Rhys Lewis, Lorna Helen Mitchell
-
Patent number: 11872221Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.Type: GrantFiled: January 29, 2021Date of Patent: January 16, 2024Assignee: HUA Medicine (Shanghai) Ltd.Inventors: Li Chen, Shuang Ren, Jiayi Zhang
-
Patent number: 11866452Abstract: A biphenyl compound represented by formula (I), a preparation method therefor and an application thereof. The present invention also relates to a pharmaceutical composition that comprises the compound as an active ingredient. The compound is a novel small molecule immunomodulator having excellent oral absorption features and can be used for treating and/or preventing various immunity-related diseases.Type: GrantFiled: October 28, 2021Date of Patent: January 9, 2024Assignee: Shenzhen Chipscreen Biosciences Co., Ltd.Inventors: Qianjiao Yang, Song Shan, Lijun Xin, Desi Pan, Xiaoliang Wang, Yonglian Song, Yu Zhang, Huiyun Huang, Qi Wei, Zhibin Li, Xianping Lu
-
Patent number: 11865079Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.Type: GrantFiled: February 10, 2022Date of Patent: January 9, 2024Assignee: Servier Pharmaceuticals LLCInventor: Chandra Agarwal Prakash
-
Patent number: 11851419Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: November 18, 2021Date of Patent: December 26, 2023Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
-
Patent number: 11851405Abstract: A dialkyl carbonate is prepared by reacting urea with an alkyl monohydric alcohol at 70° C. to 150° C. under normal pressure or reduced pressure. The reaction is conducted for 6 h to 30 h under stirring and reflux, with one or more of magnesium, calcium, aluminum, chromium, manganese, iron, cobalt, nickel, copper and zinc as a primary catalyst and one or more compounds including an electron-donating nitrogen, phosphonis, oxygen or sulfur atom as a catalyst promoter. The dialkyl carbonate is prepared under low reaction temperature and normal pressure or reduced pressure, with high selectivity and high yield. With simple operations, high safety and low cost for the process, the method has prominent industrial application prospects.Type: GrantFiled: March 16, 2018Date of Patent: December 26, 2023Inventors: Yongcheng Lei, Yongzhong Lei
-
Patent number: 11844784Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.Type: GrantFiled: June 2, 2023Date of Patent: December 19, 2023Assignee: SLAYBACK PHARMA LLCInventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian